TY - JOUR T1 - Association between Stage 1 Hypertension Defined by the 2017 ACC/AHA Hypertension Guideline and Cardiovascular Risk: A Large Cohort Study from the UK JF - medRxiv DO - 10.1101/2020.04.19.20071514 SP - 2020.04.19.20071514 AU - Fu-Rong Li AU - Xian-Bo Wu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/02/2020.04.19.20071514.abstract N2 - Importance The 2017 American College of Cardiology (ACC)/American Heart Association (AHA) hypertension (HTN) guideline lowered the threshold for HTN from 140/90 mmHg to 130/80 mmHg for systolic/diastolic blood pressure (SBP/DBP), resulting in a newly defined stage 1 HTN with an SBP/DBP reading of 130–139/80–89 mmHg. Few studies have assessed the impact of the redefined HTN on cardiovascular outcomes among the UK population.Objective To examine the effects of the revised ACC/AHA stage 1 HTN blood pressure parameters on the prevalence of HTN and related cardiovascular disease (CVD) risk in a large UK population.Design Adult men and women from a national cohort study in the UK.Setting The UK Biobank Study.Participants A total of 470,625 adults (mean age 56 years) with available data on blood pressure (BP) and without a history of CVDs at baseline.Main outcome measures Incident composite CVD outcome.Methods Prospective CVD events were analysed for survival in relation to BP measures using Cox proportional hazards regression models, adjusting for potential confounders. The associations are described by hazard ratios (HRs) and 95% confidence intervals (CIs).Results By adopting the 2017 ACC/AHA HTN guideline, an additional 24.7% of the participants were classified as having ACC/AHA stage 1 HTN, which resulted in a prevalence of HTN of 75.1% at baseline. During a mean follow-up period of 8.1 years, ACC/AHA stage 1 HTN (130–139/80–89 mmHg) was associated with a significantly increased risk of CVD (HR 1.20; 95% CI 1.10–1.30) compared to the risk associated with a normal BP (<120/80 mmHg). The excess risk of CVD associated with ACC/AHA stage 1 HTN was mainly driven by myocardial infarction (HR 1.19; 95% CI 1.05–1.36) and haemorrhagic stroke (HR 1.40; 95% CI 1.08–1.81), rather than ischaemic stroke (HR 1.02; 95% CI 0.87–1.19) and CVD death (HR 1.07; 95% CI 0.90–1.26).Conclusions The adoption of the 2017 ACC/AHA guideline would lead to a dramatic increase in the prevalence of HTN in the UK Biobank cohort study. Evidence from the present national cohort study may support lowering the threshold for HTN from 140/90 mmHg to 130/80 mmHg in the UK.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementSponsored by Open Project of Guangdong Provincial Key Laboratory of Tropical Disease ResearchAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets and code used for the current study are available from the corresponding author on reasonable request. Example code used for the analysis is available on GitHub. https://github.com/epimath/cm-dag ER -